Integrated analysis of DNA methylation, immunohistochemistry and mRNA expression, data identifies a methylation expression index (MEI) robustly associated with survival of ER-positive breast cancer patients

Jonine D. Figueroa, Howard Yang, Montserrat Garcia-Closas, Sean Davis, Paul Meltzer, Jolanta Lissowska, Hisani N. Horne, Mark E. Sherman, Maxwell Lee

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Identification of prognostic gene expression signatures may enable improved decisions about management of breast cancer. To identify a prognostic signature for breast cancer, we performed DNA methylation profiling and identified methylation markers that were associated with expression of ER, PR, HER2, CK5/6, and EGFR proteins. Methylation markers that were correlated with corresponding mRNA expression levels were identified using 208 invasive tumors from a population-based case–control study conducted in Poland. Using this approach, we defined the methylation expression index (MEI) signature that was based on a weighted sum of mRNA levels of 57 genes. Classification of cases as low or high MEI scores was related to survival using Cox regression models. In the Polish study, women with ER-positive low MEI cancers had reduced survival at a median of 5.20 years of follow-up, HR = 2.85 95 % CI = 1.25–6.47. Low MEI was also related to decreased survival in four independent datasets totaling over 2500 ER-positive breast cancers. These results suggest that integrated analysis of tumor expression markers, DNA methylation, and mRNA data may be an important approach for identifying breast cancer prognostic signatures. Prospective assessment of MEI along with other prognostic signatures should be evaluated in future studies.

Original languageEnglish (US)
Pages (from-to)457-466
Number of pages10
JournalBreast Cancer Research and Treatment
Volume150
Issue number2
DOIs
StatePublished - 2015

Fingerprint

DNA Methylation
Methylation
Immunohistochemistry
Breast Neoplasms
Messenger RNA
Survival
DNA Fingerprinting
Poland
Tumor Biomarkers
Transcriptome
Proportional Hazards Models
Neoplasms
Population
Genes
Proteins

Keywords

  • Breast cancer
  • Methylation
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Integrated analysis of DNA methylation, immunohistochemistry and mRNA expression, data identifies a methylation expression index (MEI) robustly associated with survival of ER-positive breast cancer patients. / Figueroa, Jonine D.; Yang, Howard; Garcia-Closas, Montserrat; Davis, Sean; Meltzer, Paul; Lissowska, Jolanta; Horne, Hisani N.; Sherman, Mark E.; Lee, Maxwell.

In: Breast Cancer Research and Treatment, Vol. 150, No. 2, 2015, p. 457-466.

Research output: Contribution to journalArticle

Figueroa, Jonine D. ; Yang, Howard ; Garcia-Closas, Montserrat ; Davis, Sean ; Meltzer, Paul ; Lissowska, Jolanta ; Horne, Hisani N. ; Sherman, Mark E. ; Lee, Maxwell. / Integrated analysis of DNA methylation, immunohistochemistry and mRNA expression, data identifies a methylation expression index (MEI) robustly associated with survival of ER-positive breast cancer patients. In: Breast Cancer Research and Treatment. 2015 ; Vol. 150, No. 2. pp. 457-466.
@article{c8690cf287314cbea2ea4dd919a4a94b,
title = "Integrated analysis of DNA methylation, immunohistochemistry and mRNA expression, data identifies a methylation expression index (MEI) robustly associated with survival of ER-positive breast cancer patients",
abstract = "Identification of prognostic gene expression signatures may enable improved decisions about management of breast cancer. To identify a prognostic signature for breast cancer, we performed DNA methylation profiling and identified methylation markers that were associated with expression of ER, PR, HER2, CK5/6, and EGFR proteins. Methylation markers that were correlated with corresponding mRNA expression levels were identified using 208 invasive tumors from a population-based case–control study conducted in Poland. Using this approach, we defined the methylation expression index (MEI) signature that was based on a weighted sum of mRNA levels of 57 genes. Classification of cases as low or high MEI scores was related to survival using Cox regression models. In the Polish study, women with ER-positive low MEI cancers had reduced survival at a median of 5.20 years of follow-up, HR = 2.85 95 {\%} CI = 1.25–6.47. Low MEI was also related to decreased survival in four independent datasets totaling over 2500 ER-positive breast cancers. These results suggest that integrated analysis of tumor expression markers, DNA methylation, and mRNA data may be an important approach for identifying breast cancer prognostic signatures. Prospective assessment of MEI along with other prognostic signatures should be evaluated in future studies.",
keywords = "Breast cancer, Methylation, Survival",
author = "Figueroa, {Jonine D.} and Howard Yang and Montserrat Garcia-Closas and Sean Davis and Paul Meltzer and Jolanta Lissowska and Horne, {Hisani N.} and Sherman, {Mark E.} and Maxwell Lee",
year = "2015",
doi = "10.1007/s10549-015-3314-6",
language = "English (US)",
volume = "150",
pages = "457--466",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Integrated analysis of DNA methylation, immunohistochemistry and mRNA expression, data identifies a methylation expression index (MEI) robustly associated with survival of ER-positive breast cancer patients

AU - Figueroa, Jonine D.

AU - Yang, Howard

AU - Garcia-Closas, Montserrat

AU - Davis, Sean

AU - Meltzer, Paul

AU - Lissowska, Jolanta

AU - Horne, Hisani N.

AU - Sherman, Mark E.

AU - Lee, Maxwell

PY - 2015

Y1 - 2015

N2 - Identification of prognostic gene expression signatures may enable improved decisions about management of breast cancer. To identify a prognostic signature for breast cancer, we performed DNA methylation profiling and identified methylation markers that were associated with expression of ER, PR, HER2, CK5/6, and EGFR proteins. Methylation markers that were correlated with corresponding mRNA expression levels were identified using 208 invasive tumors from a population-based case–control study conducted in Poland. Using this approach, we defined the methylation expression index (MEI) signature that was based on a weighted sum of mRNA levels of 57 genes. Classification of cases as low or high MEI scores was related to survival using Cox regression models. In the Polish study, women with ER-positive low MEI cancers had reduced survival at a median of 5.20 years of follow-up, HR = 2.85 95 % CI = 1.25–6.47. Low MEI was also related to decreased survival in four independent datasets totaling over 2500 ER-positive breast cancers. These results suggest that integrated analysis of tumor expression markers, DNA methylation, and mRNA data may be an important approach for identifying breast cancer prognostic signatures. Prospective assessment of MEI along with other prognostic signatures should be evaluated in future studies.

AB - Identification of prognostic gene expression signatures may enable improved decisions about management of breast cancer. To identify a prognostic signature for breast cancer, we performed DNA methylation profiling and identified methylation markers that were associated with expression of ER, PR, HER2, CK5/6, and EGFR proteins. Methylation markers that were correlated with corresponding mRNA expression levels were identified using 208 invasive tumors from a population-based case–control study conducted in Poland. Using this approach, we defined the methylation expression index (MEI) signature that was based on a weighted sum of mRNA levels of 57 genes. Classification of cases as low or high MEI scores was related to survival using Cox regression models. In the Polish study, women with ER-positive low MEI cancers had reduced survival at a median of 5.20 years of follow-up, HR = 2.85 95 % CI = 1.25–6.47. Low MEI was also related to decreased survival in four independent datasets totaling over 2500 ER-positive breast cancers. These results suggest that integrated analysis of tumor expression markers, DNA methylation, and mRNA data may be an important approach for identifying breast cancer prognostic signatures. Prospective assessment of MEI along with other prognostic signatures should be evaluated in future studies.

KW - Breast cancer

KW - Methylation

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84925443374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925443374&partnerID=8YFLogxK

U2 - 10.1007/s10549-015-3314-6

DO - 10.1007/s10549-015-3314-6

M3 - Article

C2 - 25773928

AN - SCOPUS:84925443374

VL - 150

SP - 457

EP - 466

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -